PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis
Author Information
Author(s): Yuhong Yang, Anne R. Gocke, Amy Lovett-Racke, Paul D. Drew, Michael K. Racke
Primary Institution: The Ohio State University Medical Center
Hypothesis
PPAR-α agonists could provide a therapy for human autoimmune diseases such as multiple sclerosis.
Conclusion
PPAR-α agonists have shown potential in regulating immune responses and ameliorating experimental autoimmune encephalomyelitis.
Supporting Evidence
- PPAR-α is expressed in various immune cells, indicating its role in immune regulation.
- PPAR-α agonists have been shown to reduce inflammation and cytokine production in experimental models.
- Gemfibrozil and fenofibrate, PPAR-α agonists, have been effective in ameliorating symptoms of experimental autoimmune encephalomyelitis.
Takeaway
PPAR-α helps control inflammation in the body, and medicines that activate it might help treat diseases like multiple sclerosis.
Methodology
This review discusses the role of PPAR-α in immune response regulation and its potential therapeutic effects in autoimmune diseases.
Limitations
The detailed mechanisms of how PPAR-α regulates immune responses are not completely understood.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website